Every Form 4 that Olema Pharmaceuticals, Inc. (OLMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OLMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OLMA filings page.
Olema Pharmaceuticals, Inc. (OLMA) reported that its Chief Financial Officer, Jason O'Byrne, received a grant of stock options covering 650,000 shares of common stock on September 1, 2026. The options have an exercise price of $10.56 per share and expire on August 31, 2036.
According to the award terms, 25% of the shares subject to the option vest on August 11, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to his continuous service. Following this grant, he holds stock options for 650,000 shares directly.
Olema Pharmaceuticals director Cyrus Harmon reported selling a total of 25,000 shares of common stock in open-market or private transactions on July 23 and 24, 2026, at weighted average prices of $11.579 and $11.714 per share, respectively. An additional 117,028 shares are reported as held indirectly by Harmon Family Investors LLC, where Harmon is the manager.
Olema Pharmaceuticals director-affiliated investment entities reported updated holdings and a new equity award arrangement. Funds and entities associated with Biotechnology Value Fund and Mark N. Lampert jointly report common stock, stock options and pre-funded warrants and collectively disclaim beneficial ownership beyond their pecuniary interests.
A key update is a grant of 29,500 stock options with an exercise price of $9.51 per share, linked to director Gorjan Hrustanovic. These options vest in 12 equal monthly installments starting June 18, 2026, or sooner at Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service.
The filing also lists substantial pre-funded warrants, each exercisable for one share of common stock at $0.0001 per share, subject to a 9.99% ownership cap to limit how many shares can be held immediately after any exercise.
Olema Pharmaceuticals director Harmon Cyrus received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Cyrus holds 29,500 stock options directly.
The options vest in 12 equal monthly installments starting June 18, 2026, conditioned on continued service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if not already fully vested, also subject to continued service.
Olema Pharmaceuticals director Cynthia M. Butitta received a grant of 29,500 stock options for common stock. The options have an exercise price of $9.51 per share and were awarded as compensation, not through an open-market purchase.
The options vest in 12 equal monthly installments starting on June 18, 2026, as long as she continues in service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if the grant is not already fully vested by then.
Olema Pharmaceuticals director Garland J. Scott received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Scott holds options for 29,500 shares directly.
The options vest in 12 equal monthly installments starting on June 18, 2026, subject to continuous service. Any unvested portion will vest in full on the date of Olema’s next annual stockholder meeting if the option is not already fully vested by then.
Olema Pharmaceuticals director Gorjan Hrustanovic received a grant of stock options for 29,500 shares of common stock at an exercise price of $9.51 per share. The options expire on June 18, 2036 and vest in 12 equal monthly installments starting June 18, 2026, with any remaining unvested portion vesting in full on the date of Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service. Under a pre-existing arrangement, any economic benefit from the sale of shares issued upon exercise is payable to BVF Partners L.P., and Hrustanovic disclaims beneficial ownership except for any pecuniary interest.
Olema Pharmaceuticals director Ian T. Clark received a new stock option grant. The award covers 29,500 shares of common stock at an exercise price of $9.51 per share and expires on June 18, 2036. The option vests in 12 equal monthly installments starting on June 18, 2026, with all remaining unvested shares vesting earlier on the date of Olema’s next annual stockholder meeting if it occurs sooner, in each case subject to his continued service.
Olema Pharmaceuticals director Yi Larson received a grant of stock options covering 29,500 shares of Common Stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036.
The 29,500 options vest in 12 equal monthly installments measured from June 18, 2026, subject to continued service. Any unvested options will instead fully vest on the date of Olema’s next annual meeting of stockholders, if earlier and if service continues through that date.
Olema Pharmaceuticals director Sandra Horning received a new stock option grant. The award covers 29,500 shares of common stock at an exercise price of $9.51 per share and expires on June 18, 2036.
The options vest in 12 equal monthly installments starting June 18, 2026, subject to her continuous service. Any remaining unvested portion will fully vest on the date of Olema’s next annual stockholder meeting if it occurs before the monthly schedule is complete.
Olema Pharmaceuticals director Raman Prakash received a stock option grant for 29,500 shares of common stock. The option has an exercise price of $9.51 per share and expires on June 18, 2036. It was awarded as compensation rather than purchased on the open market.
The 29,500 underlying shares vest in 12 equal monthly installments starting on June 18, 2026, as long as Prakash continues in service through each vesting date. Any unvested portion will fully vest on the date of Olema’s next annual stockholder meeting if it is not already fully vested and he remains in service through that date.
Olema Pharmaceuticals director Andrew Rappaport received a new stock option grant as part of his compensation. He was awarded options covering 29,500 shares of Olema common stock at an exercise price of $9.51 per share, held directly. The options expire on June 18, 2036.
The grant vests in 12 equal monthly installments starting June 18, 2026, as long as he continues to serve the company. If the options are not fully vested earlier, they vest in full on the date of Olema’s next annual stockholder meeting, again subject to continued service.
Olema Pharmaceuticals director Graham G. Walmsley received a new stock option grant for 29,500 shares of common stock. The option has an exercise price of $9.51 per share and expires on June 18, 2036. The award vests in 12 equal monthly installments starting June 18, 2026, with any remaining unvested portion vesting in full on the date of Olema’s next annual stockholder meeting, in each case contingent on his continued service. Following this grant, Walmsley holds 29,500 stock options directly.
Olema Pharmaceuticals director Raman Prakash received two stock option grants as equity compensation. The awards cover a combined 27,061 shares of common stock at an exercise price of $14.59 per share, expiring on April 27, 2036.
Options on 24,150 shares vest in full on June 11, 2026, while options on 2,911 shares vest in 36 equal monthly installments starting April 28, 2026. All vesting is conditioned on Prakash’s continuous service with the company.
Olema Pharmaceuticals’ chief legal officer Mitchell Shawnte reported option exercises and related stock sales. On March 3–4, 2026, she exercised options for a total of 40,000 shares of common stock at $4.37 per share and sold 40,000 shares in open-market transactions at weighted average prices around the mid‑$20s. Following these trades, she reported 410,000 stock options outstanding and no directly held common shares.
Olema Pharmaceuticals reported that its VP of Finance and Controller, Sasha Lu Austin, acquired equity awards on February 2, 2026. The awards include a stock option for 29,250 shares at an exercise price of $0.00 and a grant of 11,700 shares of common stock, both recorded as awards rather than open-market purchases.
According to the vesting terms, 25% of the option shares vest on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. All holdings are reported as direct ownership.
Olema Pharmaceuticals, Inc. reported that Chief Medical Officer Naseem Zojwalla received two stock option awards on February 2, 2026. She was granted stock options for 250,000 shares of common stock at an exercise price of $25.65 per share, vesting 25% on February 2, 2027 and then in equal monthly installments over the following 36 months, contingent on continued service.
She also received performance stock options covering 106,250 shares at the same exercise price. These are eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds over a 30‑day average, and subject to her continued service when the Compensation Committee certifies achievement.
Olema Pharmaceuticals granted new equity awards to a senior executive. Chief Discovery & Non-Clinical Development Officer Myles David C. received stock options for 250,000 shares at an exercise price of $25.65 per share, expiring on February 1, 2036.
For this time-based option, 25% of the shares vest on February 2, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service. He also received 106,250 performance-based stock options at the same exercise price, eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds and continued service at the certification dates.
Olema Pharmaceuticals’ chief legal officer, Shawnte Mitchell, received new stock-based awards. On February 2, 2026, Mitchell was granted stock options to buy 220,000 shares of common stock at an exercise price of $25.65 per share, expiring February 1, 2036.
These time-based options vest 25% on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. Mitchell was also granted 56,250 performance-based stock options at the same $25.65 exercise price, also expiring February 1, 2036.
The performance options may vest in two performance periods beginning February 2, 2026 and ending December 31, 2029 and December 31, 2030, if Olema’s stock achieves specified average price thresholds over a 30-day trading period and the compensation committee certifies achievement, subject to Mitchell’s continued service.
Olema Pharmaceuticals reported new equity awards to President and CEO Sean Bohen. On February 2, 2026, he received a stock option to buy 850,000 shares at an exercise price of $25.65. These options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years, subject to continued service.
On the same date, Bohen also received 275,000 performance-based stock options at an exercise price of $25.65. These can vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, if Olema’s share price meets specified thresholds over a 30-day trading average and the compensation committee certifies achievement. If his service is terminated without cause, these performance options remain eligible to vest for 12 months.
Olema Pharmaceuticals director Cyrus Harmon reported a sale of company stock. On January 20, 2026, he sold 10,000 shares of Olema Pharmaceuticals common stock at a weighted average price of $26.88 per share, with individual trade prices ranging from $26.85 to $26.96. Following this transaction, he directly held 727,770 common shares.
The filing also notes an additional 117,028 common shares held indirectly through Harmon Family Investors LLC, where Harmon serves as manager, reflecting his indirect beneficial ownership interest alongside his direct holdings.
Olema Pharmaceuticals director Harmon Cyrus reported an open-market sale of common stock. On January 14, 2026, he sold 3,489 shares of Olema Pharmaceuticals, Inc. common stock at a weighted average price of $29.12 per share, with individual trade prices ranging from $29.00 to $29.23.
After this transaction, Cyrus beneficially owns 737,770 shares directly. He also reports 117,028 additional shares held indirectly through the Harmon Family Investors LLC, of which he is the manager.
Olema Pharmaceuticals, Inc. chief operating and financial officer Shane William Charles Kovacs reported selling company common stock in two open-market transactions. On January 13, 2026, he sold 3,822 shares at a weighted average price of $28.01, within a price range of $28.00 to $28.03. On January 15, 2026, he sold 100,000 shares at a weighted average price of $28.73, within a price range of $28.50 to $29.18.
Following these transactions, Kovacs directly owned 139,727 shares of Olema Pharmaceuticals common stock.
Olema Pharmaceuticals executive David C. Myles reported multiple stock option exercises and share sales. On January 13 and 14, he exercised a total of 100,000 stock options at an exercise price of $4.87 per share, resulting in 50,000 stock options remaining outstanding. Over January 13–14, he sold 100,000 shares of common stock in the market at weighted average prices ranging from $27.60 to $28.99 per share, leaving 542,761 shares held directly.
An entity associated with him, Myles Properties Inc., sold 10,000 shares on January 12 at a weighted average price of $28.34, and continued to hold 144,846 shares indirectly. A family trust associated with him held an additional 12,831 shares indirectly. The filing also notes that a prior Form 4 overstated his directly owned shares by 120 shares due to a scrivener's error, which is corrected here.
Olema Pharmaceuticals, Inc. director reported an option exercise and a subsequent charitable gift of common stock. On 11/21/2025, the reporting person exercised a stock option and acquired 35,868 shares of Olema common stock at an exercise price of $0.39 per share. After this exercise, the same number of shares was held directly.
On 11/25/2025, the reporting person transferred 35,868 shares as a bona fide gift for no consideration to the Rappaport Family Foundation, a charitable foundation where the reporting person serves as an officer and has voting and dispositive power over the securities it owns. Following the reported transactions, the reporting person no longer holds Olema shares directly but reports 385,965 shares held indirectly through the Rappaport Family Trust, of which the reporting person is co‑trustee.
Olema Pharmaceuticals director Cyrus Harmon reported open-market sales totaling 25,000 common shares across two trading dates in September 2025, reducing his direct holdings from 754,140 to 744,140 shares and his indirect holdings (via Harmon Family Investors LLC, which he manages) from 120,114 to 117,028 shares. The reported weighted-average sale prices ranged from about $8.02 to $8.37, with specific weighted averages of $8.04 and $8.33 for direct sales and $8.08 and $8.32 for indirect sales. The Form 4 discloses the manager relationship for the indirect holdings and provides ranges and weighted averages for the trades.